Announcement

Collapse
No announcement yet.

Plegridy Update from AAN 2016

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Plegridy Update from AAN 2016

    At the US Food and Drug Administration (FDA)–approved every-2-weeks dosing schedule, peginterferon β-1a (Plegridy, Biogen Idec) maintains efficacy for up to 6 years in adults with relapsing-remitting multiple sclerosis (RRMS), new long-term data suggest.

    Over 6 years, the adjusted ARR was significantly improved with peginterferon β-1a every 2 weeks compared with the -4-weeks regimen (0.188 vs 0.263; rate ratio, 0.714; 95% confidence interval, 0.563 - 0.904; P = .0052). Year-over-year adjusted ARRs were generally reduced in the every-2-weeks group.


    http://www.medscape.com/viewarticle/862335

    #2
    Tried to go to this hyperlink, but had to Sign Up for something. Guess I will research it on my own, but thanks for posting it
    Peace to all,
    LM
    RRMS 11/11/2005, SPMS 20011 (guess I 'graduated')

    Comment

    Working...
    X